Continued migraine treatment for young patients
Treatments studied
Part of Brain & nervous system clinical trials.
This program lets children and teens who finished a previous fremanezumab study keep receiving the medication. It is designed to provide continued treatment access under their doctor's supervision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have already completed all parts of the earlier research study (TV48125-CNS-30084).
- Your doctor agrees that continuing the study medication is safe and appropriate for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies eptinezumab, a migraine treatment, in children and teens ages 6 to 17 who already completed an earlier migraine study. It mainly helps doctors learn whether the treatment can be continued safely and effectively over time.
This study follows kids and teens who already took part in an earlier migraine medication study to check long-term safety and comfort with oral ubrogepant tablets. It may help families understand whether this migraine tablet is safe to keep using over time.
This study tests an add-on migraine medicine (eptinezumab) given in the emergency room to quickly relieve a migraine attack, in addition to the usual care. It aims to see if this approach reduces pain and prevents the migraine from coming back.
This study looks at ways to help children and teens with migraine headaches by testing a care approach that includes access to evidence-based treatment. It may help if your child has frequent migraine headaches and is starting (or not already on) certain migraine-preventive medicines.
This trial studies whether rimegepant can reduce how often migraine attacks happen in children and teens. It also looks at safety and how well the treatment fits day-to-day life and school activities.
This trial tests if eptinezumab can stop a migraine attack that is already happening. It may help people who get migraines often and are already part of the TACHIS study.
Hear when a new Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.